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Abstract: Cellular senescence is a key component of human aging that can be induced by a range of
stimuli, including DNA damage, cellular stress, telomere shortening, and the activation of oncogenes.
Senescence is generally regarded as a tumour suppressive process, both by preventing cancer cell
proliferation and suppressing malignant progression from pre-malignant to malignant disease. It may
also be a key effector mechanism of many types of anticancer therapies, such as chemotherapy,
radiotherapy, and endocrine therapies, both directly and via bioactive molecules released by senescent
cells that may stimulate an immune response. However, senescence may contribute to reduced
patient resilience to cancer therapies and may provide a pathway for disease recurrence after cancer
therapy. A new group of drugs, senotherapies, (drugs which interact with senescent cells to interfere
with their pro-aging impacts by either selectively destroying senescent cells (senolytic drugs) or
inhibiting their function (senostatic drugs)) are under active investigation to determine whether they
can enhance the efficacy of cancer therapies and improve resilience to cancer treatments. Senolytic
drugs include quercetin, navitoclax, and fisetin and preclinical and early phase clinical data are
emerging of their potential role in cancer treatments, although none are yet in routine use clinically.
This article provides a review of these issues.
Keywords: senescence; cancer; aging; frailty; senolytics; senotherapies; geriatric oncology
1. An Aging Population and Cancer
In the western world, life-expectancy has doubled in the past 200 years and, whilst most of the
early gains were in childhood longevity, in the past 70 years the majority of gains have been in older
people [1,2]. Consequently, the global proportion of people over 65 is predicted to increase from 18%
now to 26% in 2041 [3]. The oldest old group of over 85 year olds is also predicted to double over the
same period, from 2 to 4% [3]. This increase in lifespan has been accompanied by an increase in rates of
chronic disease. Consequently, life-span has outpaced health-span [4], as the burden of chronic health
conditions has increased in this older population. As a result almost 50% of over 75s have 2 or more
chronic health conditions [3].
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One such age-related condition is cancer. Cancer is more common in older age groups with
predictions of substantial increases in the next 15 years of approximately 50% in developed countries,
(largely due to the increase in the older population), and even higher in developing and middle income
countries [5]. Aging interacts with cancer in a range of ways: some of the molecular pathways and
causes of aging [6] and the pathways and causes of cancer [7] overlap significantly. Aging is integral to
the causation of many cancers and also impacts on treatment response, prognosis, treatment allocation,
and treatment tolerance. One of the key processes of aging—senescence—links aging and cancer
together, and this is the focus of this article.
2. Biological Changes of Aging and Senescence
Aging is a complex process involving multiple factors, including genetic and epigenetic alterations
to DNA, cellular damage from reactive oxygen species (ROS) produced by incomplete aerobic
metabolism, age-dependent decline in mitochondrial function, stem cell exhaustion, and telomere
shortening [6,8]. The rate at which aging occurs is highly variable and depends on both polygenic
hereditary factors [9] and a wide range of environmental factors (such as obesity, diet, exercise,
and exposure to drugs and chemicals), which is why biological and chronological age are often
mis-matched. A key factor in the aging process is cellular senescence. Senescent cells are rare in the
tissues of young organisms but become more common as tissues age, especially in adipose tissue,
muscle, and skin [10].
At a cellular level senescence refers specifically to a progression of complex changes culminating
in the loss of proliferative potential (which may be reversed in some circumstances), the inhibition
of cellular apoptosis, chromatin alterations, and metabolic and synthetic changes. Senescent cells
release a complex, cell type-specific, mixture of bioactive molecules (senescence-associated secretory
phenotype or SASP), which impacts on the adjacent cells and extracellular matrix and contributes to
age-related tissue degeneration.
Senescence is increasingly recognized as a heterogeneous group of cell states, depending on
the type, degree, and duration of stimuli that triggered it [11]. Senescence may also be categorized
as acute or chronic, depending on the size and duration of the stimulus. Acute senescence is a
short-term process, often triggered to limit an inflammatory response or physiological process, such as
wound healing or embryological development [12]. Chronic senescence is triggered by feedback loops
when the senescent stimulus is prolonged, and may cause diseases such as atherosclerosis, arthritis,
neurodegenerative disease, and diabetes [13] as well as effecting classical age-related decline in tissue
function [14].
There are several regulatory pathways through which senescence may be stimulated under
appropriate conditions. These include the pathways for cellular proliferation (the cell cycle and
its regulatory machinery), the regulation of apoptosis, the DNA damage response (DDR) pathway,
cellular energy metabolism, and the unfolded protein response (UPR) [15]. In turn, senescence may
impact on these same pathways via positive or negative feedback loops as well as other intracellular
pathways and extracellular processes, such as the immune modulation, inflammation [16], regulation,
and maintenance of the extracellular matrix, and angiogenesis [17]. Consequently, senescence can have
wide ranging impacts on tissue structure and function.
Many of these pathways are also involved in the process of cancer development, suppression,
progression, recurrence, and response to therapies (Figure 1). The interactions of senescence and cancer
are therefore complex and poorly understood at present.
It has been proposed that, whilst senescence itself is largely tumour suppressive [18], the SASP
of chronically senescent cells may promote tumour recurrence or progression [19]. There are also
potential interactions with cancer therapies, in particular, radiotherapy and chemotherapy, which may
trigger either cell death at high doses or senescence at non-lethal doses. This induced senescence may
be viewed as a cytostatic clinical response, but some of these therapy induced senescent cells may
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reactivate and lead to recurrence [20–22]. They may also be an opportunity for tumour targeting to
enhance cell killing.
In addition, senescent cells, by contributing to the pathogenesis of the aging phenotype (frailty,
sarcopenia, lack of resilience, and aging-related disease) [14], impact on the ability of a patient
with cancer to tolerate a range of cancer therapies. Consequently, there is great academic interest
in senescence, and researchers have developed reliable methods to identify these cells in tissue
sections [23]. No one marker alone is sufficient to identify senescence and most researchers use a panel
of biomarkers, such as senescence-associated β-galactosidase, p21, and p16INK4A, as well as a number
of other biomarkers, such as heterochromatin and proliferation markers (Table 1) combined [24] with a
marker of cellular proliferation (Ki-67, for instance).
Interest is also growing in a new group of drugs called senotherapies. These are drugs that
either suppress the process of senescence or destroy senescent cells, and which may have potential in
cancer therapy.

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Figure 1. Diagram showing the causal stimuli which may trigger senescence (in yellow) and the effects
of senescence on the host tissue (in blue).
Table 1. Summary of the key characteristics of senescent cells.
Characteristic Marker
Proliferative arrest Low expression of Ki-67 or bromodeoxyuridine BrdU
Persistent activation of the DNA damage response
Activation of tumour suppressors, such as p53,
p16INK4A, cyclins, and cyclin-dependent kinases
Heterochromatic foci (DNA becomes denser than
normal)
Senescence-associated heterochromatic foci on DNA
staining with DAPI
Cells become flattened and enlarged Light microscopy changes
Altered metabolism including increased
β-galactosidase activity, which is part of
carbohydrate metabolism
Measurement of β-galactosidase levels
Senescence-associated secretory phenotype
Interleukins-1, -6, and -8, matrix metalloproteinases,
plasminogen activator inhibitor-1
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3. Regulatory Pathway of Senescence
The regulation of senescence is complex and incompletely understood, and a detailed review
is beyond the scope of this article, but excellent reviews are available [13,25]. A range of factors
may trigger senescence, including cell stressors, such as reactive oxygen species, DNA damage due
to aging, radiation, and genotoxic substances (including many chemotherapy agents), age-related
telomere shortening, adverse growth conditions, tumour suppressor gene activation, and oncogene
activity. (These are summarized in Figure 1). Several key pathways into senescence have
been described: replicative senescence, oncogene-induced senescence, stress-induced senescence,
and therapy-induced senescence.
3.1. Replicative Senescence
The process of senescence activation is closely linked to cell cycle regulatory machinery. The Gap
One (G1) phase may progress to the synthetic (S) phase or be side tracked into a reversible state of
dormancy (G0), terminal differentiation, or senescence (usually, but not always, causing irreversible
cell cycle arrest) depending on the activation of a range of cell cycle regulatory proteins. Key triggers
for the activation of this G1-S phase checkpoint are telomere shortening and DNA damage.
Cells have a finite ability to replicate (the Hayflick Limit [26]) and once this limit is reached,
they lose the ability to divide but remain alive and metabolically active as senescent cells. One of the
key effectors of this transition is telomere shortening. Telomeres are tandem repeats of a TTAGGG
nucleotide found at the end of all chromosomes that are progressively lost with each cell division.
Once the remaining telomere is critically shortened, it triggers a DNA damage response (DDR), which
induces proliferative arrests via the p53/cyclin E/CDK2/RB pathway that controls the cell cycle G1 to
S phase checkpoint. As telomere shortening is irreversible in normal cells and cannot be repaired,
it triggers senescence rather than temporary proliferative arrest.
The same pathway is triggered by non-lethal DNA damage, which again activates the DDR. DNA
damage accumulates progressively with age but also occurs in the majority of cancers, where a key
initiation event is often the loss of function of critical DNA repair pathways via loss of function of
tumour suppressor genes. For example, the p53 and BRCA genes are key tumour suppressor genes
that are mutated and lose function at an early stage in the process of cancer development. Again,
if this DNA damage cannot be repaired, the cell may die (usually via apoptosis) or enter senescence
via the p53/cyclin E/CDK2/RB signaling pathway. Whether a cell undergoes apoptosis or senescence
depends on the degree of damage, and whether it is repairable. In this context, senescence is tumour
suppressive in that it prevents the damaged cell from proliferating. This pathway to senescence is a
key effector of chemotherapy and radiotherapy damage.
3.2. Oncogene-Induced Senescence
Another regulatory pathway for senescence activation is via the p16 inhibitor of kinase 4(INK4),
a regulatory protein that inhibits CDK4/6 and cyclin 2 and so blocks cell cycle progression via the RB
protein. This pathwaymaybe stimulatedby the loss of tumour suppressor function, oncogene activation,
epigenetic changes (DNA methylation, for example, which may alter gene expression), or damage to
the microtubules forming the mitotic spindles (a mechanism of action of some chemotherapy agents,
such as vinca alkaloids and taxanes). Once again, mild stimulation induces senescence whereas severe
stimulation induces cell death.
3.3. Stress-Induced Senescence
Some oncogenes, such as the BRAF oncogene (which is commonly mutated in melanoma),
may trigger senescence acting via mitochondrial pyruvate kinase metabolism to regulate cell cycle
progression. Metabolic stress may also induce senescence and trigger the unfolded protein response
(UPR). This pathway, which is designed to protect the cell from exporting misfolded proteins due to
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adverse environmental conditions, is activated by a range of cell stressors, such as hypoxia, acidosis,
or other metabolic stresses. It triggers cell cycle arrest and senescence if the stressor is prolonged.
The UPR is often activated in many cancers [27] due to their abnormal microcirculation (which leads to
cellular hypoxia and acidosis) and the high glucose needs of tumours (Warberg effect), resulting in
metabolic stress.
4. Senescence-Associated Secretory Phenotype, SASP
Whereas acute senescence is largely beneficial in the regulation of transient injury or stress, if a cell
experiences prolonged non-lethal stress, a chronic senescent state is entered where the continued
production of SASP perpetuates cellular and extracellular matrix damage and results in the acquisition
of an aging or disease linked phenotype.
Senescent cells release SASP factors that damage nearby non-senescent cells and the extracellular
matrix, triggering inflammation, fibrosis, and apoptosis of adjacent healthy cells, but the senescent
cells themselves are resistant to these effects and accumulate, thus generating more SASP factors.
The precise content of the SASP released by a senescent cell may vary according to the host tissue and
the degree and type of senescent stimulus. In some cases, the SASP may have a beneficial effect—when
triggered acutely in wound healing, for example, the SASP is involved in triggering inflammation and
an immune response and, once wound closure has occurred, the myofibroblasts become senescent
to prevent excessive fibrosis. Similarly, during embryogenesis senescence is a mechanism whereby
certain processes may be physiologically stopped [12].
The SASP is a melange of over 100 molecules, including inflammatory cytokines, growth factors,
and proteases. These include interleukins 1 and 6 (pro-inflammatory cytokines that may trigger or
promote inflammation), interleukin 8 (which attracts neutrophils towards a tissue and stimulates their
activity in the inflammatory process), and matrix metalloproteinases (which break down the various
components of the extracellular matrix, such as collagen). The SASP of a particular senescent cell type
may have a tumour suppressive function and trigger immune activation or promote tumour growth
and inflammation depending on the host tissue. This variation in function makes study complex,
as senescent cells in different tissues secrete slightly varying mixtures of SASP factors and so the
inhibition of senescent cells may have positive or negative effects on cancer growth.
5. Role of Senescence in the Development of Cancer
Senescence is a keymechanism of tumour suppression. Thismay bemediated by the DNAdamage
response or via key oncogenes. Several key oncogenes, including ras, cyclin E, raf, and E2F3 expression,
are linked to senescence induction and may have a tumour suppressive role [28–30]. This may be
via the inhibition of proliferation of malignant cells or by stimulating immune surveillance. Studies
have demonstrated high levels of senescence in premalignant lesions and lower levels in invasive
disease, suggesting a role for senescence in blocking malignant progression [2,31,32]. Mutations in
key oncogenes often trigger senescence to eliminate premalignant cells before they acquire further
mutations and become invasive [33]. There is evidence of senescence being triggered by the ras
oncogene during lung and pancreatic tumorigenesis [2]. Some mechanisms to evade senescence are
therefore a key feature of malignant progression from pre-malignant to invasive disease. It has been
proposed that a loss of one of the key senescence effectors, such as the tumour suppressors p16INKA4 or
p53, may be mechanisms whereby the failure of senescence occurs [2]. This allows the oncogene to
stimulate progression without check. Senescent cells may evoke an anti-tumour immune response—so
called “senescence surveillance”—mediated by the cytokines within SASP. This has been shown to
suppress the progression of malignancy in hepatocytes in a mouse model [34]. Other mechanisms of
tumour suppression have been proposed [35].
In contrast there is also evidence that stromal cell senescence may have a tumour promoting effect
in some models—this may be because of the proangiogenic influence of some components of SASP,
such as vascular endothelial growth factor (VEGF) or the impact of senescent fibroblasts on adjacent
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tumour cells [17,36]. There is also evidence that “immune senescence”, associated with the aging of
the immune system in older age may contribute to the failure of immune surveillance and contribute
to cancer development in older people. This was shown in a study where telomere shortening in
peripheral blood T cells, was linked to the development of cancer [37].
6. Role of Senescence as a Prognostic Marker for Cancer
Senescent cells are more common in the normal tissues of aged individuals, especially in certain
tissue types, such as skin and adipose tissue [38–40]. They are also present in cancer and in premalignant
lesions and have been evaluated as prognostic markers [41]. The detection of senescence is complicated,
as many of the molecules involved in senescence signalling are also oncogenes or tumour suppressors
that may be up or down regulated as part of the carcinogenic process. The assessment of combinations
of markers is therefore required in addition to a marker of proliferation, such as Ki67. Common
markers of senescence include β-galactosidase activity, p16INK4A, p21, and heterochromatin levels
combined with a marker of proliferative arrest [23].
Markers of senescence have been assessed in a number of human cancers. In breast cancer,
p16 levels correlate with breast cancer subtype, proliferative status, and prognosis [42]. Another
study of breast cancer demonstrated that the increased expressions of senescence markers p14ARF and
p16INK4a were associated with increased risk of disease recurrence and poor survival outcomes [43].
Another study of a range of cancer types, including breast, lymphoma, colon, sarcoma and lung, found
that senescence markers were linked to better prognosis [29]. Colon and endometrial cancers have also
been studied, as well as senescence markers linked to improved prognosis [44,45]. Table 2 shows a
summary of a range of studies linking senescence with tumour prognosis.
Table 2. Table summarising studies of senescence as a prognostic biomarker in various types of cancer.
Model Cancer Type
Prognostic Significance of
Senescence
Reference
Ex vivo human tumours Breast
Senescence indicates better
survival
Althubiti et al. 2014 [29]
Ex vivo human tumours
Hepatocellular
carcinoma
Panel of seven senescence
associated genes has
prognostic significance
Xiang et al. 2019 [46]
Ex vivo human tumours
Squamous head and
neck cancer
Senescent cells associated
with a non-significant trend
to improved prognosis
Schenker et al. 2017 [47]
Ex vivo human tumours Colorectal cancer
Lower levels of senescence
associated with poorer
survival
Roxburgh et al. 2013 [48]
Ex vivo human tumours
Lymph node tissue from
Hodgkin Lymphoma
High levels of senescence
marker expression linked to
improved prognosis
Calio et al. 2015 [49]
Ex vivo human tumours
Hepatocellular
carcinoma
Low levels of senescence
linked to poor prognosis
Mo et al. 2016 [50]
Ex vivo human tumours Renal cell cancer
Low levels of senescence
linked to worse prognosis.
Macher-Goeppinger et al.
2013 [51]
7. Role of Senescence in Cancer Treatment Response
Chemotherapy
Chemotherapy may cause cell death, often by apoptosis, resulting clinically in tumour regression.
It may also cause cellular senescence, leading clinically to tumour stasis (growth arrest) (Figure 2).
Many types of chemotherapy cause DNA damage (DNA strand breaks or cross linking), which can,
if severe, cause cell death via the DNA damage response, or they may trigger a non-lethal DDR, leading
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to acute or chronic senescence, depending on the extent and duration of the stimulus [52]. Entry
into senescence or cell death may also depend on whether the cell has functional tumour suppressor
genes, such as p53 or p16INK4A to regulate cell behaviour [53]. Moderate chemotherapy doses are
more likely to cause senescence and higher doses more likely to cause cell death [54]. Different types
of chemotherapy damage DNA in a number of different ways. For example, doxorubicin prevents the
resealing of the DNA double helix by inhibiting topoisomerase 2, which triggers a DDR and thereby
may cause senescence [54]. Others, such as vinca alkaloids and taxanes, work by causing damage
to the mitotic spindle during mitosis, resulting in cell death. Cyclophosphamide causes DNA cross
linking, which again may trigger a DDR.

Figure 2. Schematic illustration of some chemotherapy-triggered responses in cancer cells. Most
chemotherapeutic drugs induce DNA damage and activate the DDR. If the extent of damage is severe,
the cell may die—e.g., through apoptosis. If the damage is sub-lethal, the cell may enter a state of
senescence. This senescence response may represent a mechanism of inducing clinical tumour stasis
(growth arrest) but in some situations such growth-arrested cells may re-enter the cell cycle and cause
disease recurrence. In addition, the release of SASP by senescent cells may contribute to tumour
recurrence as well as having an immune stimulatory function. The balance of these various processes
will vary, depending on the host tissue and the type and degree of stimuli.
The role of senescence in response to chemotherapy is more complicated, however, in that the
SASP of senescent cells induced by treatment varies between tissues and cell types, according to
the precise senescent stimulus [55]. In particular, some senescent cells secrete exosomes [56] (small
“packages” containing a variety of proteins and mRNA) and these may have a tumour promoter
function [55]. Consequently, senescence induced by some cancer therapies may be harmful and
promote tumour growth.
In a mouse model, lymphomas induced by the myc oncogene responded to cyclophosphamide
by undergoing senescence mediated by p16INK4A and p53 [57]. It has been hypothesised that the
induction of permanent senescent cytostasis may be an effective strategy for cancer treatment, rather
than killing the cancer cell [58], and may have reduced toxicity. However, there are concerns that these
senescent cells may serve as a potential reservoir for resistance if their senescent state is reversed.
There are some human data about the role of senescence in chemotherapy response in lung, breast,
and prostate cancer and lymphoma. In breast cancer cases treated with neoadjuvant chemotherapy,
41% of tumours were stained by senescence markers compared to only 10% of untreated cases,
showing that senescence is induced by CAF (cyclophosphamide, Adriamycin, and fluorouracil)
chemotherapy [53]. Senescence is also an important mechanism of efficacy in the treatment of breast
cancer with PARP inhibitors [59] and many typical chemotherapy agents used to treat breast cancer,
such as epirubicin and cyclophosphamide [60]. The treatment of breast cancer cells with Adriamycin for
5 days induces 60% of cells to become senescent [61]. A very small study of neoadjuvant chemotherapy
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in patients with non-small cell lung cancer showed increased senescence biomarkers in patients
treated with a taxane and carboplatin [62]. Similarly, in prostate cancers treated with neoadjuvant
mitozantrone, elevated levels of senescence biomarkers were found [31,63]. Similarly, senescence has
been seen in chemotherapy-treated lymphoma [64].
Whilst cells that undergo apoptosis are permanently removed from a cancer, senescent cells remain
and secrete various inflammatory cytokines, which may have both positive and negative impacts [65].
There have been concerns that these senescent cells may resist further chemotherapy damage and be a
potential reservoir for recurrence. There is evidence that senescent cells may also be re-programmed to
re-enter the cell cycle after certain types of chemotherapy [20,21,62] and may acquire a more “stem
cell”-like phenotype, which may in turn contribute to tumour regrowth and evolution [66,67]. Recently,
another form of tumour dormancy has been described whereby multinucleate senescent giant cells may
re-enter the cell cycle and produce viable diploid daughter cells whichmay repopulate a tumour [68,69].
Conversely, there is evidence that the secretion of SASP factors may enhance the immune
surveillance of tumours and induce bystander cells to become senescent thereby inhibiting tumour
progression [66]. It can be seen from the above that the role of senescence in the response of cancer to
chemotherapy is highly complex and more research is needed to clarify these interactions.
8. Role of Senescence in Radiotherapy
Radiotherapy, which is one of the mainstays of cancer therapy, acts by causing direct DNA damage
and has wide ranging impacts on cancer cells mediated by reactive oxygen species. The DNA damage
response is triggered and if repair is not possible, cells either die if the damage is severe or enter
senescence if less severe. In irradiated cancer cells, the percentage of senescent cells therefore increases
in the remaining “radio-resistant” clones [70]. The concern is that these senescent cells may be released
from senescence and assume a more “stem cell”-like phenotype, which may result in aggressive
recurrence [71]. Cerebral glioblastoma, in which radiotherapy induces senescent multinucleate giant
cells to form and reactivate these cells, is now recognized as an important mechanism of relapse [72].
In contrast, radiotherapy also triggers an immune response, making the treated cells more
immunogenic in a variety of ways [73]. Part of this immunogenicity may be due to the release of SASP
factors from senescent cells.
Another way in which senescence may be a clinically important part of radiotherapy response is
in causing radiation-induced fibrosis. This can be a potentially severe complication of radiotherapy,
especially in the lung where pulmonary fibrosis may occur [74]. Senescent cells also appear to be
linked to skin fibrosis and ulceration following radiotherapy [75]. Senolytic agents may have a role in
abrogating this fibrotic response, although to date there have been no human trials to evaluate this.
9. Role of Senescence in Response to Hormonal Therapies (Anti-Oestrogens, Anti-Androgens)
The mechanism of action of antioestrogen therapies in breast cancer and the mechanisms of
resistance are very complex, but senescence may be one of the pathways activated when disease
responds to antioestrogens [76]. Similarly androgen deprivation therapy induces senescence in prostate
cancer cells and the SASP has been implicated in disease progression [77].
10. Role of Senescence in Surgery
Surgery is the single most important curative modality in the treatment of most human solid
tumours, and cure is unlikely without it for most cancer types. Successful surgery, however, requires
wound healing for recovery. Wound healing is a complex multistep process and senescence may be
involved in both positive and negative ways.
After an initial haemostatic phase, an inflammatory response is triggered, and a range of cells
migrate into the area or differentiate locally to effect healing. Collagen synthesis and remodelling
occur, and the skin re-epithelializes. A wide range of cells, biologically active molecules, and signalling
systems that both start and stop the process are involved. At an early stage in the process, senescent
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epithelial cells and fibroblasts appear and induce myofibroblast differentiation by secretion of platelet
derived growth factor AA (PDGF-AA), which is a component of the SASP [78]. These myofibroblasts
assist healing by the secretion of collagen and, by their contractile properties, help to draw the wound
together (contraction). In addition, senescence is involved in “switching off” the healing process to
prevent excess fibrosis. Matrix metalloproteinases within the SASP help to degrade collagen as part of
remodelling [79]. Consequently, the failure of senescence may have a detrimental effect on wound
healing, as seen in a mouse model where senescent cells were eliminated, resulting in disorganised
collagen remodelling [78].
Conversely, chronic senescence has been causally implicated in non-healing ulcers [75] and
delayed wound healing in diabetes, for example [80]. Levels of senescent fibroblasts are correlated
with the length of time taken by venous ulcers to heal [81]. Wound healing is impaired in older
organisms [82] for a variety of reasons and it is known that the skin is an area where senescent cells
accumulate with age.
Few studies have directly assessed the relationship with senescence and surgical outcomes;
however, p16 expression is negatively correlated with liver regeneration after hepatectomy in older
patients [83] and the molecular aging marker CDKN2A has been shown to predict renal allograft
function after 1 year in renal transplant patients [84].
It is therefore not clear what impact senolytic therapies might have on wound healing in the acute
surgical setting and this requires urgent further study if these agents are to be adopted into clinical
practice. This is especially important in this era of multimodal therapy regimes. If senotherapies are
used as adjuncts to chemotherapy, it would be critical to ensure any negative impacts on wound healing
are resolved before surgery. Similarly, if senotherapies are used to enhance resilience to surgery, the
acute effect on wound healing must be properly evaluated. There are currently no studies published of
senotherapies on acute wound healing.
11. Frailty and Senescence Reducing Resilience to Cancer Therapies
Older patients are less resilient to many cancer therapies. This is due, in part, to comorbidity
rates being higher in older people, but also due to age-related organ dysfunction and frailty. Frailty
is present in approximately 25% of the older surgical population and is linked to longer hospital
stays and higher post-surgical mortality rates [85,86]. Adverse events are also more likely following
chemotherapy [87]. Biomarkers of frailty are generally linked to the presence of chronic low grade
inflammation [88] and a range of inflammatory markers have been studied and correlate with poor
treatment outcomes across a range of diseases [89]. It is thought that SASP factors may contribute to
this age and frailty-linked inflammation, and its abrogation may alleviate it [14].
This principle was elegantly demonstrated in a mouse model, where the implantation of senescent
cells into young mice induced physical dysfunction, which spread beyond the injected senescent cells
and reduced lifespan. In contrast, treating naturally aged mice or senescent cell injected mice with the
senolytic drug combination of dasatinib and quercetin both reduced the number of senescent cells and
caused a reduction in physical dysfunction and extended lifespan [14].
In the context of chemotherapy tolerance, there is evidence that some of the adverse effects of
chemotherapy are mediated by the therapy-induced senescent cells which have a pro-inflammatory
effects (due to SASP) in a doxorubicin or paclitaxel treated mouse model [67]. Removal of these
therapy-induced senescent cells abrogated many of the adverse effects of chemotherapy (reduced
fatigue, increased activity levels, reduced cardiac functional impairment) [67]. In a separate study,
again in a mouse model, the elimination of senescent cells by the use of dasatinib and quercetin,
reduced the impact of radiotherapy, improved cardiac function and exercise tolerance and increased
life expectancy [90]. Data in humans are also available that show that higher levels of senescence
biomarkers are linked with higher rates of treatment-induced adverse events following doxorubicin
chemotherapy [67].
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12. Senotherapies
This term refers to a group of pharmacological agents that interact with senescent cells to interfere
with their pro-aging impacts. There are two main categories: senolytic drugs, which selectively destroy
senescent cells and senostatic drugs, which inhibit their function by suppression of their release of
SASP factors. Of the two drug groups, senolytics have been more extensively studied and show
promise of therapeutic value. These are of particular interest as an adjunct to chemotherapy, where the
senolytic drug may be able to target cells induced to become senescent by the cancer. They may also
improve treatment resilience. There are several agents under investigation.
12.1. Navitoclax
Navitoclax interacts with the BCL-2 pathway and prevents it from inhibiting apoptosis, causing
the senescent cells to undergo apoptosis [91]. The rationale is that the chemotherapy drug causes
cells to undergo either apoptosis or senescence and the Navitoclax then induces the senescent cells to
undergo apoptosis by inhibiting BCL-2 [92]. This should therefore enhance cell killing.
There is widespread evidence that Navitoclax potentiates the effect of a range of anticancer
therapies in vitro and in vivo (Table 3), but efficacy in clinical studies has been limited by toxicity,
in particular thrombocytopenia, which significantly limits its dose in human studies. Response rates for
both single agent and combination studies have been disappointing (Table 3). There have been recent
attempts to increase the specificity of Navitoclax to senescent cells by combining the drugwith galactose.
As senescent cells have higher levels of the galactosidase enzyme (SA β-galactosidase), the release of
active Navitoclax is targeted to the senescent cells, potentially reducing platelet toxicity [93]. There are
currently a few early phase clinical trials in progress, but unless the toxicity issue can be addressed it
may not have a role in routine oncology practice.
Table 3. Table showing studies of Navitoclax in a range of cancer models and trials.
Reference Model Drug Cancer Type Effect
Tan et al. 2011 [94] In vitro Naviticlax+Paclitaxel
Non-small cell lung
cancer
More than additive cell
killing with combination
Stamelos et al. 2013
[95]
In vitro
Naviticlax+Paclitaxel or
Carboplatin
Ovarian cancer
More than additive cell
killing with combination
Jeong et al. 2019
[96]
In vitro Vemurafenib+Navitoclax
Papillary thyroid
cancer
Enhanced growth arrest
and increase apoptosis
with combination
Nakajima et al.
2016 [97]
In vitro Vorinostat+Navitoclax
Small cell lung
cancer
Increased induction of
apoptosis with
combination
Gonzalez-Gualda
et al. 2020 [93]
In vitro and ex
vitro
Galactose conjugated
Navitoclax+Cisplatin
Lung cancer
Increased cell killing with
combination. Reduced
platelet toxicity in ex vivo
blood
Ackler et al. 2012
[98]
In vivo mouse
model
Bendamustine+Navitoclax
±Rituximab
Non-Hodgkins
lymphoma
Enhanced efficacy in
combination
Tolcher et al. 2015
[99]
Phase 1 clinical trial Irinotecan+Navitoclax
Advanced solid
tumours, n = 31
6% rate of partial response
Kipps et al. 2015
[100]
Phase 2 clinical trial Rituximab+Navitoclax
Chronic lymphocytic
lymphoma
Combination increase
progression free survival
and response rates
Rudin et al. 2012
[101]
Phase 2 clinical trial Single agent navitoclax
Relapsed small cell
lung cancer, n = 39
23% static disease, 2.6%
partial response
12.2. Dasatinib Plus Quercetin
The combination of dasatinib (a tyrosine kinase inhibitor) plus quercetin (a flavonoid) (D +Q)may
act in part via senescence induction, although this combination has quite wide-ranging cellular impacts.
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It reduces levels of senescent cells in a range of in vitro models and in mouse in vivo models [14,90].
That D + Q acts principally by senolytic effects for particular conditions, as opposed to effects on
these other pathways, has been indicated in studies of, for example, osteoporosis. In mice with
age-related osteoporosis, D + Q is as effective in restoring bone if administered once every few weeks
as opposed to continuously despite D + Q having an elimination half-life of less than 11 h. Senescent
cells take weeks to reappear. Thus, it seems very unlikely that in osteoporosis the beneficial effects
of D + Q are due to mechanisms requiring continuous engagement of a classical biochemical target,
such as occupancy of a receptor or inhibiting an enzyme, and senolytic “hit and run” effects are more
plausible [102]. Consistent with this, in the case of frailty, which can be induced in younger healthy
mice by transplanting senescent cells, a brief course of D +Q eliminates senescent cells and causes long
term resolution of frailty [14]. Thus, the development of successful senolytics has more in common
with developing antibiotics than the old fashioned one target-one drug-one disease drug development
paradigm [103,104].
While D + Q has been shown to reduce levels of senescent cells in a range of in vitro models and
in mouse in vivo models [14,90], to date there are few clinical trial data of its efficacy in the cancer
setting, although some evidence in non-cancer settings. For example in pulmonary fibrosis, where
it is thought that the secretome of senescent fibroblasts mediates fibrosis, Quercetin and Dasatinib
reduce this effect in vivo [105]. In a cancer setting, it has been used to reduce radiation-induced skin
ulceration in a mouse model by reducing senescent cells in the skin [75]. In human subjects, senescent
cells may be implicated in the development of radiation-induced skin ulceration as shown recently by
a study where p16 expression was associated with radiation-induced ulcers in human subjects [75].
This is potentially of great interest as radiation induced fibrosis and ulceration are a major cause of
morbidity following radiotherapy in clinical practice.
12.3. Fisetin
Flavonoids are a group of naturally occurring chemicals found widely in fruit and vegetables
and which are well known for their beneficial antioxidant properties. Studies looking at the senolytic
properties of a range of flavonoids have found that fisetin is potent [106,107] and roughly twice as
potent as quercetin, with an excellent toxicity profile in animal studies [108]. High levels are found
in strawberries, apples, persimmons and lower levels in grapes and cucumbers [109]. It has been
extensively investigated in vitro and in vivo, where it has wide ranging effects on a number of key
pathways involved in cell cycle regulation, apoptosis, the suppression of inflammation, angiogenesis,
and metastasis (reviewed in Kashjap at al. [109]). It has been investigated in studies of combined
treatment with other anticancer agents to determine whether it may potentiate their effect. These
studies are summarised in Table 4.
Table 4. Table summarising studies of fisetin in cancer.
Reference Model Drug Cancer Type Effect
Li et al., 2018 [110]
In vitro and in vivo
mouse xenograft
Fisetin alone
Triple negative
breast cancer
Inhibition of proliferation,
migration and metastases
Xiao et al., 2018 [111]
In vitro and in vivo
mouse xenograft
Fisetin and fisetin micelles Ovarian cancer
Antiproliferative and
proapoptotic effects
Jia et al., 2019 [112]
In vitro and in vivo
mouse xenograft
Fisetin alone Pancreatic cancer Antiproliferative
Youns et al., 2017
[113]
In vitro Fisetin alone
Hepatic, colorectal,
and pancreatic
Growth arrest and apoptosis
Yan et al., 2018 [114] In vitro Fisetin alone Gastric cancer
Antiproliferative and
pro-apoptotic
Yang et al., 2012 [115] In vitro Fisetin alone Breast cancer Induction of apoptosis
Lin et al., 2015 [116] In vitro and in vivo Fisetin and sorafenib Cervical cancer
Combination superior to either
agent alone in anticancer efficacy
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Table 4. Cont.
Reference Model Drug Cancer Type Effect
Pal et al., 2015 [117]
In vivo mouse
model
Fisetin and sorafenib
BRAF mutated
melanoma cells
Reduced proliferation, increased
apoptosis and reduced metastases
in combination
Khan et al., 2019
[118]
In vivo mouse
model
Fisetin and 5FU Colorectal cancer
Reduced incidence of colorectal
cancer formation with Fisetin
alone and in combination
Zhuo et al., 2015
[119]
In vitro Fisetin and cisplatin
Lung
adenocarcinoma
Increased apoptosis and decreased
viability with combination
Touil et al., 2011 [120]
In vivo mouse
model
Fisetin and
cyclophosphamide
Lung cancer
92% growth inhibition of
combination compared to
single agent
Farsad-Naemi et al.,
2018 [121]
Randomised
clinical trial of
dietary supplement
dose of Fisetin
Oxaliplatin and
capecitabine
chemotherapy ± Fisetin
100 mg daily for 7 weeks
Colorectal cancer
Reduced levels of inflammatory
mediators (IL8, CRP and MMP7)
in Fisetin group. Tumour
response was not reported
It is already available for human consumption in low doses as a nutritional supplement as 100 mg
capsules where it is marketed to enhance brain health. To put this into context, the average daily
consumption of Fisetin is thought to be 0.4 mg per day [109]. In terms of clinical trials, this 100 mg dose
has been used in a colorectal cancer chemotherapy study and has been shown to reduce inflammatory
markers, although numbers were small and no clinical cancer end points were assessed [121]. There
were no safety issues at this dose and the research team felt there was potential for further studies to
investigate its adjuvant value.
There is an on-going phase 2 trial (ClinicalTrials.gov Identifier: NCT03675724, AFFIRM_LITE)
looking at much higher doses, (20 mg/kg orally for 2 days, so roughly 10- to 15-fold higher than the
previous study, with an average 70 kg person getting 1400 mg per day). The study is evaluating the
impact of fisetin on a range of biomarkers in older women with frailty syndrome [122]. The initial
results are awaited. It is hoped that the AFFIRM LITE study will demonstrate the safety of higher
dose Fisetin, to permit clinical trials to assess the potential impact of Fisetin on resilience, age-related
dysfunction, and chronic diseases, and as an adjunctive treatment for cancer.
12.4. Metformin
As a result of these interactions, there has been recent interest in the use of adjuvant senolytics
and senostatics to selectively remove or inhibit senescent cells. For example, the diabetic drug,
metformin has senostatic properties and reduces the stimulatory effect of SASP intermediates on
prostate cancer cells [123] and is effective in reducing the incidence (chemoprevention) of a range of
different cancers [124]. Whether this is due to its senostatic activities or to its impact on metabolism is
not yet clear.
12.5. Other Agents
A number of other agents with senotherapeutic potential are under investigation. These include
HSP90 chaperone inhibitors [125] (such as geldanamycin) and FOXO4 p53 interfering peptide. Whilst
trials are in progress with some of these agents, none are yet approved for clinical use. A note of caution
is needed in that, whilst some cancers and cancer treatments may react positively to senotherapies,
the variation in SASP composition [55] may mean that these findings cannot be extrapolated to other
cancers and treatment types.
13. Impact of Frailty on Cancer Treatment and Outcomes
There is another way inwhich senolytics may impact on cancer outcomes—by enhancing resilience
and reducing frailty. It is already recognised that long-term survivors of cancer have increased rates of
frailty and reduced longevity, some of which are thought to be due to the direct and indirect induction
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of senescent cells by cancer therapies (chemotherapy and radiotherapy). A trial is currently running to
assess the impact of senolytic therapy on stem cell transplant survivors using dasatinib and quercetin
in a small number of patients and assessing the impact on frailty [126].
Another important patient group is the elderly with cancer. It is well recognized that treatments
such as surgery and chemotherapy have a significant negative impact on physical function, with
studies showing an increase in measures of frailty after treatment, which may never recover back to
baseline levels. This loss of function is one of the reasons that older patients require longer hospital
admission after surgery and sometimes require social care support in the longer term after surgery.
This physical dysfunction is therefore a major burden on both the NHS and social care resources and
is a research priority for the UK government. If use of senolytic therapies could reduce the frailty
phenotype and enhance resilience, this would be a major advance in cancer therapies.
14. Conclusions
As can be seen from the above, senescence is a complex process closely related to cell cycle
regulatory processes and is integral to human aging and the genesis of many human diseases.
It is thought to be a tumour suppressive process, inhibiting both the formation of cancer by blocking
transition from premalignant to malignant disease and preventing damaged cells from proliferating
after suffering DNA damage or cellular stress, which is one of the key events promoting cancer
development. Senescence is also a key effector mechanism of many chemotherapy agents, both directly
induced but also via the immune stimulator effects of the SASP. Conversely, it may be a route to tumour
resistance and recurrence if the senescent cells reacquire the ability to proliferate when they may
become more stem-cell like or via the proinflammatory and apoptosis inhibitory effects of the SASP.
Senotherapies may become a valuable adjunct to cancer therapies both by direct destruction of
the chemotherapy-induced senescent cell population within a tumour and by the inhibition of the
proinflammatory SASP, which may enhance treatment tolerance by the patient.
Research into the potential of a range of senotherapies is rapidly growing and hopefully new
agents will enter clinical practice in the near future.
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